公开(公告)号：US20240352085A1

公开(公告)日：2024-10-24

申请号：US18602534

申请日：2024-03-12

申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

发明人： Qiuhong LI ,  Mohan RAIZADA

IPC分类号： C07K14/575 ,  A61K35/00 ,  A61K35/74 ,  A61K35/741 ,  A61K35/747 ,  A61K45/06 ,  A61K48/00 ,  A61P3/00 ,  A61P3/10 ,  A61P9/12 ,  A61P27/02 ,  A61P29/00 ,  C07K7/14 ,  C07K14/195 ,  C07K14/28 ,  C07K14/47 ,  C07K19/00 ,  C12N1/00 ,  C12N9/48

CPC分类号： C07K14/575 ,  A61K35/74 ,  A61K35/741 ,  A61K35/747 ,  A61K45/06 ,  A61P3/00 ,  A61P3/10 ,  A61P9/12 ,  A61P27/02 ,  A61P29/00 ,  C07K7/14 ,  C07K14/195 ,  C07K14/28 ,  C07K14/47 ,  C07K19/00 ,  C12N1/00 ,  C12N9/485 ,  A61K2035/115 ,  A61K48/00 ,  C07K2319/02 ,  C07K2319/50 ,  C07K2319/60

摘要： Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

公开(公告)号：US12030920B2

公开(公告)日：2024-07-09

申请号：US17521121

申请日：2021-11-08

申请人： In3Bio Ltd.

发明人： Keith Alan Charlton ,  Erik D'Hondt

IPC分类号： A61K39/00 ,  C07K14/28 ,  C07K14/47 ,  C07K14/475 ,  C07K14/48 ,  C07K14/485 ,  C07K14/495 ,  C07K14/50 ,  C07K14/65 ,  C07K14/71 ,  C12N9/12 ,  C12N9/64

CPC分类号： C07K14/485 ,  A61K39/0005 ,  A61K39/0011 ,  C07K14/28 ,  C07K14/4748 ,  C07K14/475 ,  C07K14/4753 ,  C07K14/48 ,  C07K14/495 ,  C07K14/50 ,  C07K14/65 ,  C07K14/71 ,  C12N9/12 ,  C12N9/6424 ,  A61K2039/645 ,  A61K2039/70 ,  C07K2319/40 ,  Y02P20/582

摘要： A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats.

公开(公告)号：US20240058438A1

公开(公告)日：2024-02-22

申请号：US18099035

申请日：2023-01-19

申请人： The Governors of the University of Alberta ,  Helmholtz Center for Infection Research

发明人： Michael Houghton ,  Abdolamir Landi ,  Carlos A. Guzman ,  Thomas Ebensen ,  Darren Hockman ,  John L. Law ,  Michael Logan

IPC分类号： A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  A61K39/12 ,  C07K14/005 ,  A61K39/39 ,  C01F11/02 ,  C07D323/00 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86

CPC分类号： A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  A61K39/12 ,  C07K14/005 ,  A61K39/39 ,  C01F11/02 ,  C07D323/00 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86 ,  A61K2039/543

摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US20240058433A1

公开(公告)日：2024-02-22

申请号：US18267410

申请日：2021-12-13

申请人： CHAIN BIOTECHNOLOGY LIMITED

发明人： Edward Green ,  Benjamin Michael Bradley ,  Shison Jiang ,  Richard Mark Edwards

IPC分类号： A61K39/12 ,  A61K9/00 ,  A61K39/02 ,  C07K14/005 ,  C07K14/28 ,  C12N7/00

CPC分类号： A61K39/12 ,  A61K9/0053 ,  A61K39/107 ,  C07K14/005 ,  C07K14/28 ,  C12N7/00 ,  A61K2039/542

摘要： A bacterium of the class Clostridia comprising a heterologous nucleic acid molecule encoding at least one antigen, wherein the bacterium is capable of expressing the antigen in an intracellular compartment of the bacterium during anaerobic cell growth, and wherein at least one antigen is an infectious agent antigen or a tumour antigen.

公开(公告)号：US20240024388A1

公开(公告)日：2024-01-25

申请号：US18317071

申请日：2023-05-13

申请人： The University of British Columbia

发明人： Deanna Gibson ,  Artem Godovannyi ,  Sandeep Gill ,  Andrea Alejandra Verdugo-Meza

IPC分类号： A61K35/747 ,  A61P1/00 ,  C07K14/28

CPC分类号： A61K35/747 ,  A61P1/00 ,  C07K14/28

摘要： The present invention relates to probiotic compositions. More specifically, the present invention relates to probiotic compositions that are useful in reducing inflammation and/or that exhibit increased colonization or persistence in the gastrointestinal tract of a mammal.

公开(公告)号：US20190194265A1

公开(公告)日：2019-06-27

申请号：US16299928

申请日：2019-03-12

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

发明人： Roland W. Herzog ,  Henry Daniell

IPC分类号： C07K14/28 ,  A61K38/47 ,  C12N15/82 ,  C07K14/755 ,  A61K38/45 ,  A61K38/37 ,  A61K38/36

CPC分类号： C07K14/28 ,  A61K36/00 ,  A61K38/36 ,  A61K38/37 ,  A61K38/45 ,  A61K38/47 ,  C07K14/755 ,  C07K2319/00 ,  C12N15/8214 ,  C12N15/8257 ,  C12Y204/00 ,  C12Y302/0102 ,  C12Y302/01022 ,  Y02A50/471

摘要： Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine and canine hemophilia as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of a coagulation factor expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated subjects when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after four to six exposures to intravenous coagulation factor protein. Finally, the method can effectively be used to reverse or reduce undesirable pre-existing inhibitor titers.

公开(公告)号：US20180327768A1

公开(公告)日：2018-11-15

申请号：US15776602

申请日：2016-11-16

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Henry Daniell

IPC分类号： C12N15/82 ,  C07K14/435 ,  C07K14/705 ,  C07K14/47 ,  C07K14/28 ,  A61K36/00 ,  A61K9/00 ,  A61K9/48

CPC分类号： C12N15/8257 ,  A61K9/0053 ,  A61K9/48 ,  A61K36/00 ,  A61K38/00 ,  C07K14/28 ,  C07K14/435 ,  C07K14/4723 ,  C07K14/705 ,  C07K14/70596 ,  C07K14/71 ,  C07K2319/00 ,  C07K2319/60 ,  C07K2319/80 ,  C12N15/8258

摘要： Compositions and methods for producing therapeutic fusion proteins comprising targeting sequences directing the protein to cells or tissues of interest are disclosed.

公开(公告)号：US20180118792A1

公开(公告)日：2018-05-03

申请号：US15801467

申请日：2017-11-02

申请人： INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY

发明人： Kyung A. CHO ,  Jae Sung LIM ,  Joon Haeng RHEE

IPC分类号： C07K14/315 ,  A61K39/09 ,  C07K14/28 ,  A61K38/16 ,  A61K39/02 ,  A61K39/00

CPC分类号： C07K14/3156 ,  A61K38/164 ,  A61K39/092 ,  A61K39/107 ,  A61K2039/58 ,  C07K14/28 ,  C07K2319/00

摘要： The present invention relates to a composition for preventing, improving, or treating aging, wherein the composition comprises a recombinant protein of flagellin, which is the constituent of Vibrio vulnificus flagella, fused with a pathogenic protein antigen, as an active component. According to the present invention, the recombinant protein of the present invention can improve external and internal aging-related malfunctions and enhance immunity. Also, the composition of the present invention can easily perform immunization through mucosal administration.

公开(公告)号：US09845341B2

公开(公告)日：2017-12-19

申请号：US14770919

申请日：2014-03-11

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Matthew Waldor ,  Xiaohui Zhou ,  Benjamin Gewurz

IPC分类号： C07K14/28 ,  A61K35/74 ,  A61K39/02

CPC分类号： C07K14/28 ,  A61K35/74 ,  A61K39/02 ,  C07K2319/00 ,  C07K2319/20 ,  C07K2319/31 ,  C07K2319/40 ,  C07K2319/50 ,  C07K2319/60

摘要： Embodiments described are immunosuppressant therapeutics and compositions comprising a Vop protein derived from Vibro parahaemolyticus; and drug delivery vehicles derived from a V. parahaemolyticus expressing a mutant VopZ protein lacking amino acid residue 38-62.

公开(公告)号：US09611294B2

公开(公告)日：2017-04-04

申请号：US13612300

申请日：2012-09-12

申请人： Timothy Cardozo ,  Xiangpeng Kong ,  Susan Zolla-Pazner

发明人： Timothy Cardozo ,  Xiangpeng Kong ,  Susan Zolla-Pazner

IPC分类号： C07K7/64 ,  A61K38/19 ,  A61K39/21 ,  A61K39/12 ,  C07K7/08 ,  C07K14/005 ,  C07K14/245 ,  C07K16/10 ,  C07K14/28 ,  G01N33/68 ,  G01N33/569 ,  A61K39/00

CPC分类号： C07K16/1063 ,  A61K38/19 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/545 ,  A61K2039/6037 ,  A61K2039/64 ,  C07K7/08 ,  C07K7/64 ,  C07K14/005 ,  C07K14/245 ,  C07K14/28 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/55 ,  C12N7/00 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2799/023 ,  G01N33/56988 ,  G01N33/6854 ,  G01N2333/162 ,  G01N2469/20

摘要： The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.